A Phase III, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial of d-Threo-Methylphenidate HCl in Brain Tumor Patients Receiving Radiation Therapy

Butler, J.M.; Case, L. Douglas; Atkins, James N.; Frizzell, Bart; Sanders, George; Griffin, Patricia; Lesser, Glenn J.; McMullen, Kevin P.; McQuellon, Richard P.; Naughton, M.J.; Rapp, Stéphen R.; Stieber, Volker W.; Shaw, Edward G.

doi:10.1016/j.ijrobp.2007.05.076

Cited by 198 publications

(161 citation statements)

References 19 publications

Supporting

Mentioning

147

Contrasting

Unclassified

Order By: Relevance

“…The one study in humans was terminated early owing to slow accrual and high drop-out rates [51]. The data from planned or ongoing studies of neuroprotective agents in humans cited in our previous review are not yet available.…”

Section: Studies Of Pharmacological Prevention In Patients With Brainmentioning

confidence: 99%

Interventions for cognitive deficits in patients with a brain tumor: an update

Gehring

Aaronson

Taphoorn

et al. 2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

Section: Studies Of Pharmacological Prevention In Patients With Brainmentioning

confidence: 99%

Interventions for cognitive deficits in patients with a brain tumor: an update

Gehring

Aaronson

Taphoorn

et al. 2010

Expert Review of Anticancer Therapy

View full text Add to dashboard Cite

“…Meta‐analysis was performed for two studies,23, 24 which used the Functional Assessment for Chronic Illness Therapy ‐ Fatigue as the assessment tool in fatigue, comparing methylphenidate with placebo. The studies showed a slightly superior effect of methylphenidate compared with placebo (standardized mean difference 0.49, 95% confidence interval 0.15 to 0.83; Figure 2).…”

Section: Resultsmentioning

confidence: 99%

Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review

Mücke

Mochamat

Cuhls

et al. 2016

Journal of Cachexia, Sarcopenia and Muscle

View full text Add to dashboard Cite

BackgroundIn palliative care patients, fatigue can be severely debilitating and is often not counteracted with rest, thereby impacting daily activity and quality of life. Further complicating issues are the multidimensionality, subjective nature and lack of a consensus definition of fatigue. The review aimed to evaluate the efficacy of pharmacological treatments for fatigue in palliative care, with a focus on patients at an advanced stage of disease, including patients with cancer and other chronic diseases.MethodsWe considered randomized controlled trials concerning adult palliative care with a focus on pharmacological treatment of fatigue compared with placebo, application of two drugs, usual care or a non‐pharmacological intervention. The primary outcome had to be non‐specific fatigue (or related terms such as asthenia). We searched the CENTRAL, MEDLINE, PsycINFO and EMBASE, and a selection of cancer journals up to 28 April 2014. Two review authors independently assessed trial quality and extracted the data.ResultsWe screened 1645 publications of which 45 met the inclusion criteria. In total, we analysed data from 18 drugs and 4696 participants. There was a very high degree of statistical and clinical heterogeneity in the trials. Meta‐analysis of data was possible for modafinil, pemoline, and methylphenidate.ConclusionsDue to the limited evidence, we cannot recommend a specific drug for the treatment of fatigue in palliative care patients. Some drugs, which may be beneficial for the treatment of fatigue associated with palliative care such as amantadine, methylphenidate, and modafinil, should be further researched.

show abstract

“…Además, éstos incluyen pacientes paliativos no oncoló-gicos como HIV, entre otros. Se arrojaron resultados controvertidos, dos de los EC analizados apuntan hacia un beneficio sobre placebo contando con limitaciones metodológicas o de seguimiento 10,11 y otros dos no demostraron beneficio sobre el placebo 12,13 . Minton, por su parte, actualizó en 2011 14 .…”

Section: Revisiones Sistemáticasunclassified

Use of methylphenidate in palliative patients with asthenia: a review

Saralegui

Palácio

Royo

2013

Anales Sis San Navarra

View full text Add to dashboard Cite

La astenia o fatiga es uno de los síntomas más frecuentes en el paciente paliativo. Uno de los tratamientos, actualmente en evaluación, para combatir la misma es el metilfenidato. Este hecho, nos llevó a realizar una revisión de la bibliografía publicada hasta la fecha sobre su manejo, hallando al metilfenidato como un fármaco seguro que, globalmente, puede reducir la fatiga en el paciente paliativo, con un perfil de efectos secundarios tolerable. ABsTrACTAsthenia (or fatigue) is one of the most common symptoms in palliative patients. Methylphenidate is currently being assessed for treating this condition. A review of related literature published to date was performed, revealing methylphenidate to be a safe drug which could decrease fatigue in palliative patients with a tolerable side-effects profile

show abstract

A Phase III, Double-Blind, Placebo-Controlled Prospective Randomized Clinical Trial of d-Threo-Methylphenidate HCl in Brain Tumor Patients Receiving Radiation Therapy

Cited by 198 publications

References 19 publications

Interventions for cognitive deficits in patients with a brain tumor: an update

Interventions for cognitive deficits in patients with a brain tumor: an update

Pharmacological treatments for fatigue associated with palliative care: executive summary of a Cochrane Collaboration systematic review

Use of methylphenidate in palliative patients with asthenia: a review

Contact Info

Product

Resources

About